Intellia Therapeutics Head office building

Investors
& Media

Banner Menu

Press Releases

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read More

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Read More

Upcoming
Events

More events are coming soon.

Stock Information

Minimum 15 minutes delayed. Source: LSEG